A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD.

Trial Profile

A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Lisdexamfetamine (Primary) ; Methylphenidate (Primary) ; Methylphenidate; Mixed amfetamine salts
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Acronyms NOTA
  • Most Recent Events

    • 28 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Planned End Date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top